References
Abrahamsson C, Duker G, Lundberg C, Carlsson L. (1993). Electrophysiological and inotropic effects of H 234/09 (almokalant) in vitro: a comparison with two other novel IK blocking drugs, UK-68,798 (dofetilide) and E-4031. Cardiovasc Res 27:861-867.
Alexander SP, Striessnig J, Kelly E, Marrion NV, Peters JA, Faccenda E, … Davies JA. (2017). The concise guide to pharmacology 2017/18: Voltage-gated ion channels. Br J Pharmacol, 174:S160-S194.
Brignole M, Moya A, de Lange FJ, Deharo JC, Elliott PM, Fanciulli A, … van Dijk JG. (2018). ESC Guidelines for the diagnosis and management of syncope. Eur Heart J, 39:1883-1948.
Briganti A, Evangelista F, Centonze P, Rizzo A, Bentivegna F, Crovace A, Staffieri F. (2018). A preliminary study evaluating cardiac output measurement using Pressure Recording Analytical Method (PRAM) in anaesthetized dogs. BMC Vet Res, 14:72.
Champéroux P, Viaud K, El Amrani AI, Fowler JS, Martel E, Le Guennec JY, Richard S. (2005). Prediction of the risk of Torsade de Pointes using the model of isolated canine Purkinje fibres. Br J Pharmacol, 144:376-385.
Champéroux P, Ouillé A, Martel E, Fowler JS, Maurin A, Jude S, … Richard S. (2010). Interferences of the autonomic nervous system with drug induced QT prolongation: a point to consider in non-clinical safety studies. J Pharmacol Toxicol Methods, 61:251-263.
Champéroux P, Thireau J, Jude S, Laigot-Barbé C, Maurin A, Sola ML, … Le Guennec JY. (2015). Dofetilide induced QT interval short term variability and ventricular arrhythmias are dependent on high frequency autonomic oscillations. Br J Pharmacol, 172:2878-2891.
Champéroux P, Le Guennec JY, Jude S, Laigot C, Maurin A, Sola ML, … Thireau J. (2016). The high frequency relationship: implications for torsadogenic hERG blockers. Br J Pharmacol, 173:601-612.
Champéroux P, Fesler P, Judé S, Richard S, Le Guennec JY, Thireau J. (2018). High-frequency autonomic modulation: a new model for analysis of autonomic cardiac control. Br J Pharmacol, 175:3131-3143.
Chiba K, Ishizaka T, Yoshimatsu Y, Mikamoto K, Maeda Y, Iguchi T, … Mori K. (2020). Comprehensive analysis of cardiac function, blood biomarkers and histopathology for milrinone-induced cardiotoxicity in cynomolgus monkeys. J Pharmacol Toxicol Methods. 103:106870. doi: 10.1016/j.vascn.2020.106870. Epub 2020
Couderc JP (2012). The Telemetric and Holter ECG Warehouse (THEW): the first three years of development and research. J Electrocardiol, 45:677-683.
Goldenberg I, Horr S, Moss AJ, Lopes CM, Barsheshet A, McNitt S, … Zhang L. (2011). Risk for life-threatening cardiac events in patients with genotype-confirmed long-QT syndrome and normal-range corrected QT intervals. J Am Coll Cardiol, 57:51-59.
Harding SD, Sharman JL, Faccenda E, Southan C, Pawson AJ, Ireland S, … Davies JA. The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY. Nucl Acids Res 2018; 46: D1091–D1106.
Kramer J, Obejero-Paz CA, Myatt G, Kuryshev YA, Bruening-Wright A, Verducci JS, Brown AM. MICE models: superior to the HERG model in predicting Torsade de Pointes. Sci Rep, 3:2100.
Kannankeril P, Roden DM, Darbar D. (2010). Drug-induced long QT syndrome. Pharmacol Rev, 62:760-781.
Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010). NC3Rs Reporting Guidelines Working Group. Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol, 160: 1577–1579.
Kim JA, Lopes CM, Moss AJ, McNitt S, Barsheshet A, Robinson JL, … Goldenberg I. (2010). Trigger-specific risk factors and response to therapy in long QT syndrome type 2. Heart Rhythm, 7:1797-1805.
Kouchoukos NT, Sheppard LC, McDonald DA. (1970). Estimation of stroke volume in the dog by a pulse contour method. Circ Res, 26:611-23.
Le Guennec JY, Thireau J, Ouillé A, Roussel J, Roy J, Richard S, … Champéroux P. (2016). Inter-individual variability and modeling of electrical activity: a possible new approach to explore cardiac safety?. Sci Rep, 6:37948.
Lengyel C, Varró A, Tábori K, Papp JG, Baczkó I. (2007). Combined pharmacological block of I(Kr) and I(Ks) increases short-term QT interval variability and provokes torsades de pointes. Br J Pharmacol, 151:941-951.
Maltsev VA, Silverman N, Sabbah HN, Undrovinas AI. (2007). Chronic heart failure slows late sodium current in human and canine ventricular myocytes: implications for repolarization variability. Eur J Heart Fail, 9:219-227.
McGrath JC, Lilley E (2015). Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP. Br J Pharmacol, 172: 3189–3193.
Moss AJ, Schwartz PJ, Crampton RS, Tzivoni D, Locati EH, MacCluer J, … Choi S. (1991). The long QT syndrome. Prospective longitudinal study of 328 families. Circulation. 84:1136-1144.
Näbauer M, Kääb S. (1998). Potassium channel down-regulation in heart failure.
Cardiovasc Res, 37:324-334.
Nedergaard OA, Abrahamsen J. (1988). Effect of chlorpromazine on sympathetic neuroeffector transmission in the rabbit isolated pulmonary artery and aorta. Br J Pharmacol, 93:23-34.
Nourian Z, Mulvany MJ, Nielsen KB, Pickering DS, Kristensen T. (2008). The antagonistic effect of antipsychotic drugs on a HEK293 cell line stably expressing human alpha1A1-adrenoceptors. Eur J Pharmacol, 596:32-40.
O’Connell TD, Jensen BC, Baker AJ, Simpson PC. (2014). Cardiac alpha1-adrenergic receptors: novel aspects of expression, signaling mechanisms, physiologic function, and clinical importance. Pharmacol Rev, 66:308-33.
Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, … DeMets DL. (1991). Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med, 325:1468-1475.
Page A, Aktas MK, Soyata T, Zareba W, Couderc JP. (2015). ”QT clock” to improve detection of QT prolongation in long QT syndrome patients. Heart Rhythm, 13:190-198.
Park E, Gintant GA, Bi D, Kozeli D, Pettit SD, Pierson JB, …Valentin JP. Can non-clinical repolarization assays predict the results of clinical thorough QT studies? Results from a research consortium. Br J Pharmacol, 175:606-617.
Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, … Van Veldhuisen DJ. (2015). ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Eur Heart J, 36:2793-2867.
Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, … Hammond TG. (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58:32-45.
Shimizu W, Antzelevitch C. (1999). Cellular basis for long QT, transmural dispersion of repolarization, and torsade de pointes in the long QT syndrome. J Electrocardiol, 32 Suppl:177-184.
Schwartz PJ, Priori SG, Spazzolini C, Moss AJ, Vincent GM, Napolitano C, … Bloise R. (2001). Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation, 103:89-95.
Sleight AJ, Koek W, Bigg DC. (1993). Binding of antipsychotic drugs at alpha 1A- and alpha 1B-adrenoceptors: risperidone is selective for the alpha 1B-adrenoceptors. Eur J Pharmacol, 238:407-410.
Tande PM, Bjørnstad H, Yang T, Refsum H. (1990). Rate-dependent class III antiarrhythmic action, negative chronotropy, and positive inotropy of a novel Ik blocking drug, UK-68,798: potent in guinea pig but no effect in rat myocardium. J Cardiovasc Pharmacol, 16:401-410.
Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. (1996). Heart rate variability: standards of measurement, physiological interpretation, and clinical use. Circulation, 93:1043–1065.
Thomas D, Wimmer AB, Wu K, Hammerling BC, Ficker EK, Kuryshev YA, … Karle CA. (2004). Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin. Naunyn Schmiedebergs Arch Pharmacol, 369:462-472.
Thomsen MB, Verduyn SC, Stengl M, Beekman JD, de Pater G, van Opstal J, … Vos MA. (2004). Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs. Circulation, 110:2453-2459.
Viskin S, Fish R, Zeltser D, Belhassen B, Heller K, Brosh D, … Barron HV. (2000). Arrhythmias in the congenital long QTsyndrome: how often is torsade de pointes pause dependent? Heart, 83: 661–666.
Volders PGA, Stengl M, van Opstal JM, Gerlach U, Spätjens R, Beekman JDM, … Vos MA. (2003). Probing the contribution of IKs to canine ventricular repolarization: key role for beta-adrenergic receptor stimulation. Circulation, 107:2753-2760.
Yang T, Chun YW, Stroud DM, Mosley JD, Knollmann BC, Hong C, Roden DM. (2014). Screening for acute IKr block is insufficient to detect torsades de pointes liability: role of late sodium current. Circulation,130:224-234.
Yunomae K, Ichisaki S, Matsuo J, Nagayama S, Fukuzaki K, Nagata R, Kito G. (2007). Effects of phosphodiesterase (PDE) inhibitors on human ether-a-go-go related gene (hERG) channel activity. J Appl Toxicol, 27:78-85.
Zamir M, Kimmerly DS, Shoemaker JK. (2012). Cardiac mechanoreceptor function implicated during premature ventricular contraction. Auton Neurosci , 167:50-55.